Background: Surgical resection with negative margins is the only curative approach for pancreatic cancer. A paucity of data exists in using PET/CT scan as staging workup in resectable pancreatic cancer. The aim of this study is to determine if PET/CT prevents futile laparotomy by detecting occult metastatic disease in patients with resectable or borderline resectable pancreatic cancer. Methods: Patients were included using institutional PET/CT data base incorporating National Oncologic PET Registry with diagnosis of resectable or borderline resectable pancreatic cancer from 2005 to 2012. Clinical, radiographic, and pathologic characteristics were evaluated. The impact of PET/CT on patient management was estimated by calculating the percentage of patients whose treatment plan was altered secondary to PET/CT. Results: We identified 285 patients with early stage pancreatic cancer who received PET/CT as part of initial staging workup. Upon initial workup (CT + EUS), 62% of patients were considered resectable, and 38% were borderline resectable. Addition of PET/CT scan changed the management in 10.9% (n = 31) of the patients (95% CI, 8%-15%). Metastatic lesions were confirmed with biopsy in 19 patients (61%). The proportion of change in treatment plan was significantly higher in patients who were initially considered to have borderline resectable compared with resectable malignancy (17% vs 7%, P = 0.019). In 199 patients who underwent surgery, 18.1% (n = 36) were found to have metastatic disease intraoperatively. Conclusions: PET/CT helped improve detection of occult metastases, ultimately sparing these patients a potentially unnecessary surgery. The role of PET/CT scan should be validated in prospective study.
P
ancreatic cancer still remains lethal and is the fourth most common cause of cancer-related death in the United States. In 2014, approximately 46,420 individuals will be diagnosed with pancreatic cancer, and approximately 39,590 people will die of pancreatic cancer in the United States. 1 Surgical resection of the tumor with negative margins offers the only chance of cure for this disease. Diagnostic workup for pancreatic cancer to evaluate resectability includes triple phase helical scan computed tomography (CT) and endoscopic ultrasound (EUS). Some institutions may add staging laparoscopy; however this is not universally accepted because of lack of controlled studies showing benefit compared with radiographic imaging. 2 National Comprehensive Cancer Network (NCCN) guidelines recommend pancreatic CT or magnetic resonance imaging (MRI), imaging of chest, and EUS for workup of pancreatic cancer to determine its resectability. However, NCCN does not recommend fusion positron emission tomography/computed tomography (PET/CT) as a part of initial staging. 3 Studies in pancreatic cancer have shown the overall sensitivity of PET scan alone to be as high as 92% and can be potentially reliable in detecting metastatic disease in the liver. [4] [5] [6] However, there are contradictory studies demonstrating no benefit of PET scan in detecting small volume of disease in the liver or peritoneum. 7, 8 In early resectable pancreatic cancer, a paucity of data exist using PET/CT scan as staging workup with few small studies suggesting potential benefit of PET/CT scan. In a small prospective study, PET/CT changed management in 16% of patients with pancreatic cancer, and in another retrospective study, PET/CT scan altered management in 11% of patients. 9, 10 The main objective of our study was to determine if PET/CT prevents futile laparotomy in patients with resectable pancreatic cancer based on CT scan and EUS. Specifically, this study would assess if PET/CT scan detect occult metastatic disease, which was not detected by standard imaging resulting in altering the management of the patient.
PATIENTS AND METHODS

Patients
Between 2005 and 2012, an institutional review board-approved retrospective review of prospective data from Moffitt Cancer Center was recorded. We looked at our institutional PET/CT database incorporating National Oncologic PET Registry with diagnosis of pancreatic cancer. Patients with metastatic or locally advanced pancreatic cancer and intraductal papillary mucinous neoplasm (IPMNs) were excluded.
All patients were discussed in our multidisciplinary gastrointestinal tumor board before definitive treatment planning. The definition of borderline-resectable disease used at our institution includes the following criteria: (1) ≤180°circumferential tumor abutment of superior mesenteric vein (SMV), portal vein (PV), or superior mesenteric artery (SMA); (2) short segment encasement (approximately 1.5 cm) of the PV/SMVamenable to partial vein resection and reconstruction; or (3) gastroduodenal artery encasement up to the origin of the hepatic artery very similar to NCCN definition of borderline pancreatic cancer. Clinical, radiographic, and pathologic follow-up was evaluated for each patient.
As per Moffitt's pancreatic cancer pathway, all patients with suspected resectable or borderline pancreatic cancer are evaluated with 3-phase CT angiogram with pancreas protocol, CT of the chest (minimum 3 mm slices), CA 19-9, and EUS with histologic confirmation. Patients with potentially resectable/borderline disease are referred for surgical consultation. Finally, before surgical resection or neoadjuvant therapy for borderline cancer, all the patients underwent PET/CT scan.
PET/CT Scan
Metabolic tracer imaging was performed with 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography integrated with computed tomography, using either a Siemens Biograph Classic PET/CT or a General Electric Healthcare Discovery PET/CT scanner. Imaging was initiated at 90 min after intravenous injection of 296 to 555 MBq (8-15 mCi) of radiotracer. Both devices provide for the selection of a voxel within a selected volume of interest for the maximum standardized uptake rate (SUV max ), defined as the ratio of tissue radioactivity concentration at time T, C PET (T), and the injected dose at the time of injection divided by body weight, or SUV bw = C PET (T)/(injected dose/patient's weight). For any metastatic disease outside the liver and adrenal glands, an SUV max greater than 3.0 was considered positive for hypermetabolic activity. Because there is background hypermetabolic activity in the liver, a higher SUV max threshold of 5.0 was used.
Statistical Analysis
The demographic and baseline characteristics of patients were summarized using descriptive statistics. The impact of PET/CT on patient management was estimated by calculating the percentage of patients whose treatment plan was altered because of PET/CT. The corresponding 95% confidence interval for the proportion was computed using the Clopper-Pearson method. The association between categorical variables was evaluated using the Fisher's exact test. Multivariable logistic regression models were used to assess the association of change in treatment plan by PET/CT or during surgery with predictors. The predictors in the initial model included stage of primary tumor before PET, sex, age, T-N stage, location of primary tumor (head or body/tail), time interval between EUS and PET scan and baseline CA 19-9. The final model was determined using the backward elimination method. A 2-sided P < 0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
From 2005 until 2012, we initially identified 497 who underwent PET/CT imaging for newly diagnosed pancreatic cancer (Fig. 1) . Of 497 patients, we identified 285 patients who were initially found to be resectable or borderline resectable by CT scan and EUS. Patients' characteristics are listed in Table 1 . The median age of our patient cohort was 69.1 years (range, 35.5-90.6 years). All of the patients had CT scan and EUS as part of the initial workup, which was followed up by PET/ CT scan. At the GI multidisciplinary tumor board before PET scan, 109 patients (38%) were considered to have borderline resectable pancreatic cancer, and 176 (62%) patients were deemed resectable. There were 8 patients who were initially considered to have T4 lesion. However, the review of CT scan and EUS at the tumor board conference determined that 5 of these 8 patients had borderline resectable pancreatic cancer, and 3 patients had resectable disease. No FDG uptake of the primary pancreatic lesion was observed in 37 patients (13%). The median SUV uptake was 6.1 (1.9-21.4).
PET/CT in the Evaluation of Metastatic Disease
PET/CT findings changed the management in 31 patients (11%; 95% CI, 8%-15%) with pancreatic cancer who were considered to be resectable (n = 13) or borderline resectable (n = 18) after routine staging (Fig. 1) . Most of these occult lesions were found in the liver (64%), followed by the lung (13%), lymph node (19%), and adrenal gland (3%) ( Table 2) . Of these 31 patients, 19 patients (61%) underwent biopsy for pathologic confirmation of metastatic disease. The median time from CT to PET scan was 13 days (range, 0-108 days; interquartile, 1, 19 days). All patients were treated with palliative chemotherapy without surgical resection.
In addition, 4 patients had suspicious lesions for metastatic disease on the PET scan before surgery but still underwent surgical resection based on tumor board recommendation. Three patients were confirmed to have metastatic disease upon surgical exploration; liver was involved in 2 patients and omentum in 1 patient. The fourth patient had hypermetabolic activity reported in the kidney. Upon surgical exploration, this patient was found to have renal cell carcinoma in addition to pancreatic cancer. Patient underwent resection of pancreatic primary along with nephrectomy. Figures 2A and 2B are examples where liver lesion and lymph node, respectively, were not detected by routine CT scan but were detected by PET/CT scan and were positive for malignancy upon biopsy. Figure 2C is an example of cavitary lung lesion seen on CT scan and was hypermetabolic on PET scan. The lesion was histologically confirmed to be metastatic disease.
We performed the multivariate logistic regression analysis to determine the variables that are associated with change in staging by PET/ CT scan ( Table 3) . The final selected model shows that 4 variables were found to be statistically significant: pre-PET scan staging (resectable vs borderline), sex, SUVof primary pancreatic lesion, and the time interval between CT and PET scan. In our study, every 2 weeks' delay in PET scan evaluation is associated with an increased risk of finding unresectable disease by PET scan by factor of 1.38. PET scan changed the staging in 18 (17%) of the 109 patients who were initially considered to have borderline disease and 13 (7%) of the 176 patients who were deemed to have resectable cancer. Interestingly, CA 19-9 level was not significantly associated with change in resectability status by PET scan on both univariate and multivariable analysis.
Accuracy of EUS, CT, and PET/CT as Initial Staging Workup for Resectable Pancreatic Cancer
Most patients with borderline resectable cancer underwent neoadjuvant chemotherapy with GTX (gemcitabine, docetaxel, and capecitabine) for 3 cycles followed by radiation therapy and surgery as per Moffitt pancreatic cancer pathway. Patients with resectable pancreatic cancer directly proceeded to surgery. Surgical exploration for resection was performed in 199 patients. This included 148 (84%) of the 176 patients who were initially staged as resectable pancreatic cancer, and 51 (47%) of the 109 patients staged as borderline resectable pancreatic cancer. The primary reasons for not undergoing surgical resection included finding of metastatic disease on PET scan (n = 31), medically unfit for surgery (n = 11), patients' decision (n = 4), progression of disease among borderline resectable group (n = 8), lost to follow-up (n = 28), and others (n = 4).
Metastatic or unresectable disease was found in 36 patients (18%) during surgery including 17 (33%) of 51 patients originally diagnosed with borderline resectable pancreatic cancer and 19 (13%) of 148 patients originally diagnosed with resectable disease. The primary site of metastases involved liver (33%), peritoneum (25%), and large blood vessel (28%). In evaluating the association between change in staging during surgery and clinical factors, location of the primary tumor (head or body/tail) and pre-PET staging (resectable or borderline resectable) were both statistically significant in univariate and multivariable logistic regression analysis (data not shown).
DISCUSSION
Accurate initial staging for pancreatic cancer is important not only to assess local and regional disease extent but to evaluate potential distant metastatic disease to avoid futile laparotomy. There is conflicting data regarding the use of PET or PET/CT as initial workup in resectable pancreatic cancer. Earlier studies showed that PET scan or PET/CT does not add additional information to that derived from standard imaging. 11, 12 Study by Frolich et al attempted to investigate the role of PET scan in resectable disease. 5 The study demonstrated sensitivity of 68% and specificity of 95% to detect liver lesions. However, these studies included heterogeneous population including both malignant and benign disease along with early and advanced disease. Prospective study to determine the impact of PET/CT on the management of resectable suspected pancreatic cancer was conducted by Heinrich et al with 59 patients. 9 In this prospective study, PET/CT scan was able to change management in 16% (6/37) of the patients. Furthermore, authors demonstrated that PET/CT was cost effective as well. In another retrospective study, Bang et al reported that of 72 pancreatic cancer cases that were considered resectable, distant metastases were found in additional 17 patients (24%) with PET/CT. Liver was the most common site of occult metastases. 13 However, EUS was not used for staging, and not all the patients were histologically confirmed as adenocarcinoma.
Our study only included patients with histologically confirmed adenocarcinoma who had resectable or borderline resectable pancreatic cancer. We have previously published a 10% rate of upstaging in a small series of 82 patients with pancreatic cancer which also included IPMN. 10 In this study, PET/CT scan changed the management in 10.9% of the patients by detecting metastases not initially picked up by standard imaging and included both EUS and CT scan. In patients initially considered to have borderline resectable cancer, PET scan changed the resectability status in 16.5% of the patients and helped avoid futile laparotomy. In patents with resectable disease addition of PET/CT scan avoided surgery in 7.4% of the patients. The delay between CT and PET scan was associated with finding of metastatic disease by PET scan, demonstrating the importance of completing staging workup in timely fashion. Higher SUV of the primary pancreatic lesion increased the likelihood of finding metastatic disease. Majority of the metastatic lesions were found in the liver by PET/ CT scan but missed by standard imaging. To our knowledge, this is the largest report to evaluate the role of PET/CT as initial staging work up in addition to standard imaging in patients with resectable pancreatic cancer. Furthermore, this is the first study that to assess the value of PET/CT in patients with resectable and borderline resectable pancreatic cancers separately as an initial staging workup.
This study also demonstrates the limitations of PET/CT scan in evaluating resection status of pancreatic cancer patients. In patients who underwent surgery, additional 18% of patients were found to have metastatic or unresectable disease during the surgery. Most of the metastatic lesions were found in the liver and peritoneum. PET/CT is not as effective in detecting metastatic disease in the peritoneum. 7 Our findings in this study shows that, despite our modern technology, about 1 of 5 of patients are not accurately staged and may undergo unnecessary surgery. Previous studies have shown that up 30% of the patients who were deemed resectable were found to be unresectable during the laparoscopic findings. [14] [15] [16] However, none of those studies used PET/CT as initial staging. It is possible that diagnostic laparoscopy may further improve the accuracy of staging; however, to this date, there are no controlled studies demonstrating benefit of diagnostic laparoscopy. There are data to support that patients with pancreas tumor in the body or tail, or high initial tumor marker have very high chance of occult peritoneal disease. 17, 18 In our series, patients with tumors located in body or tail and initial presurgical staging of borderline pancreatic cancer were found to have higher rates of peritoneal disease as well.
Limitations of our study include retrospective design and subjectivity in interpretation of resectable pancreatic cancer. For example, there were 8 patients with T4 lesions but were considered borderline resectable or resectable when the cases were reviewed at the tumor board. At our institute, all patients with potentially resectable pancreatic cancer undergo PET/CT before the surgery. This helped reduce selection bias given the retrospective design of this study. One of the limitations of this study was that the tissue confirmation for metastatic disease was performed only for 61% of the patients. The reason for this relatively low rate was that most of the patients received treatment with the local oncologist after PET/CT confirmation of metastatic disease and did not follow up at our institute. Moreover, not all the patients who were deemed resectable after PET/CT scan underwent surgery.
We are reporting the largest series to date using PET/CT as a part of staging for early pancreatic cancer. Although the study is retrospective, PET/CT significantly changed the overall management of patients with pancreatic cancer compared with standard staging alone. This is especially true for patients with borderline resectable pancreatic cancer where PET/CT scan prevented futile laparotomy in 1 of 6 patients by detecting occult metastatic disease. Better staging workup is still needed as despite our current modern imaging techniques with PET/CT, CT and EUS, 18% of the patients (33% of patients with borderline resectable disease) were found to have metastatic or unresectable disease during surgery, which raises potential question of staging laparoscopy as part of the initial workup. These findings will be required to be validated in a prospective study along with cost effective analysis. 
